AR090455A1 - Metodos para preparar analogos de nucleotidos sustituidos - Google Patents

Metodos para preparar analogos de nucleotidos sustituidos

Info

Publication number
AR090455A1
AR090455A1 ARP130100924A ARP130100924A AR090455A1 AR 090455 A1 AR090455 A1 AR 090455A1 AR P130100924 A ARP130100924 A AR P130100924A AR P130100924 A ARP130100924 A AR P130100924A AR 090455 A1 AR090455 A1 AR 090455A1
Authority
AR
Argentina
Prior art keywords
methods
compound
formula
prepare analogs
replaced nucleotides
Prior art date
Application number
ARP130100924A
Other languages
English (en)
Inventor
Mkeon Bligh Cavan
Ibrahim Shereen
Anzalone Luigi
Liu Jyanwei
Serebryany Vladimir
Chun Jung Young
Jamison Rose Peter
Beigelman Leonid
Original Assignee
Alios Biopharma Inc
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma Inc, Vertex Pharma filed Critical Alios Biopharma Inc
Publication of AR090455A1 publication Critical patent/AR090455A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/26—Amides of acids of phosphorus containing P-halide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

Se prepara un análogo de nucleótido de fosforotioato, que resultan de utilidad en el tratamiento de enfermedades y/o en afecciones tales como las infecciones virales. Reivindicación 1: Un método para preparar un compuesto de la fórmula (1) caracterizado porque el método comprende: acoplar un compuesto de la fórmula (A) y un compuesto de la fórmula (B), donde los grupos -OH y el grupo -NH del compuesto de la fórmula (A) están desprotegidos durante la reacción de acoplamiento.
ARP130100924A 2012-03-21 2013-03-21 Metodos para preparar analogos de nucleotidos sustituidos AR090455A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613758P 2012-03-21 2012-03-21
US201261734564P 2012-12-07 2012-12-07
US13/793,900 US8846896B2 (en) 2012-03-21 2013-03-11 Methods of preparing substituted nucleotide analogs

Publications (1)

Publication Number Publication Date
AR090455A1 true AR090455A1 (es) 2014-11-12

Family

ID=49212396

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP130100924A AR090455A1 (es) 2012-03-21 2013-03-21 Metodos para preparar analogos de nucleotidos sustituidos
ARP140100826A AR095217A1 (es) 2012-03-21 2014-03-11 Métodos para síntesis estereoselectiva de análogos de nucleósidos sustituidos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP140100826A AR095217A1 (es) 2012-03-21 2014-03-11 Métodos para síntesis estereoselectiva de análogos de nucleósidos sustituidos

Country Status (9)

Country Link
US (2) US8846896B2 (es)
EP (1) EP2828278A4 (es)
CN (1) CN104334570B (es)
AR (2) AR090455A1 (es)
HK (1) HK1203513A1 (es)
NZ (1) NZ630800A (es)
TW (1) TWI617568B (es)
UY (1) UY34697A (es)
WO (1) WO2013142125A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2828278A4 (en) 2012-03-21 2015-12-09 Alios Biopharma Inc PROCESSES FOR PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
WO2013174962A1 (en) 2012-05-25 2013-11-28 Janssen R&D Ireland Uracyl spirooxetane nucleosides
CN110684067A (zh) 2012-12-21 2020-01-14 艾丽奥斯生物制药有限公司 取代的核苷和核苷酸
WO2014100498A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014164533A1 (en) * 2013-03-11 2014-10-09 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
WO2014165704A1 (en) * 2013-04-05 2014-10-09 Vertex Pharmaceuticals, Inc. Hepatitis c viral infection treatment using a combination of compounds
US9815864B2 (en) 2013-06-26 2017-11-14 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3424938B1 (en) 2013-06-26 2020-07-22 Janssen BioPharma, Inc. 4'-azidoalkyl-substituted nucleosides, nucleotides and analogs thereof
AU2014331863C1 (en) * 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
CN117379452A (zh) 2014-06-24 2024-01-12 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
AU2015280234B2 (en) 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9908914B2 (en) 2014-10-28 2018-03-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
GEAP202215528A (en) 2015-03-06 2022-11-10 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
MX383931B (es) 2015-03-11 2025-03-14 Janssen Biopharma Inc Compuestos de aza-piridona y usos de estos.
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
BR112019004297A2 (pt) 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
CN110049767B (zh) * 2016-10-03 2023-04-04 艾库斯生物科学有限公司 腺苷5′-核苷酸酶的抑制剂
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN112630314B (zh) * 2020-11-06 2022-10-28 天地恒一制药股份有限公司 一种l-丙氨酸异丙酯盐酸盐与其对映异构体的分离方法
CN112645977A (zh) * 2020-12-23 2021-04-13 天津阿尔塔科技有限公司 一种脱异丙基巴胺磷的合成方法
CN113234102A (zh) * 2021-05-18 2021-08-10 宁波大学 一种三配位磷衍生物及中间体及制备方法
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
CN1133642C (zh) * 2000-10-09 2004-01-07 清华大学 核苷5’-硫代磷酰氨基酸酯化合物
KR101774429B1 (ko) * 2009-02-06 2017-09-04 코크리스탈 파마, 아이엔씨. 암 및 바이러스 감염 치료용 퓨린 뉴클레오시드 모노포스페이트 프로드럭
MX2011009728A (es) 2009-03-20 2011-10-14 Alios Biopharma Inc Analogos nucleotido y nucleosido sustituidos.
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
CN104203253A (zh) 2012-03-21 2014-12-10 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
EP2828278A4 (en) 2012-03-21 2015-12-09 Alios Biopharma Inc PROCESSES FOR PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog

Also Published As

Publication number Publication date
US8895723B2 (en) 2014-11-25
EP2828278A4 (en) 2015-12-09
CN104334570A (zh) 2015-02-04
TW201343666A (zh) 2013-11-01
WO2013142125A1 (en) 2013-09-26
TWI617568B (zh) 2018-03-11
US8846896B2 (en) 2014-09-30
CN104334570B (zh) 2017-06-06
EP2828278A1 (en) 2015-01-28
US20130253181A1 (en) 2013-09-26
US20130281687A1 (en) 2013-10-24
UY34697A (es) 2013-10-31
NZ630800A (en) 2016-06-24
AR095217A1 (es) 2015-09-30
HK1203513A1 (en) 2015-10-30

Similar Documents

Publication Publication Date Title
AR090455A1 (es) Metodos para preparar analogos de nucleotidos sustituidos
UY39646A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
ECSP18048718A (es) Imidazolilimidazoles condensados como compuestos antivirales
MD20140112A2 (ro) Analogi carba-nucleozidici 2'-substituiţi pentru tratamentul antiviral
ECSP15031144A (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos
CA2807584C (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
NZ727392A (en) Methods of preparing substituted nucleotide analogs
MX2019003738A (es) Compuestos antivirales.
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CR20150370A (es) Compuestos antivirales
BR112014005103A2 (pt) composições orgânicas para tratar doenças associadas com hsf1
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
ECSP14013199A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
CU20170056A7 (es) Métodos para tratar infecciones por el virus filoviridae
BR112014011340A2 (pt) métodos para a preparação de análogos de nucleotídeos antivirais
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
UY33735A (es) Compuestos antivirales
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
ECSP13012417A (es) Derivados de ácido napht-2-ilacético para tratar sida
MX2014003169A (es) Ligandos del receptor ep1.
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
BR112013027098A2 (pt) produtos de vírus recombinante e métodos para inibição de expressão de miotilina
ECSP11010807A (es) Sales de los compuestos del inhibidor de vih
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure